Yi-Hong Fan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yi-Hong Fan has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Bin Lv
9 shared publicationsYi Xu
Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Zhejiang Prov Key Lab Gastrointestinal Dis Pathop, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China
5 shared publicationsJing-Jing Wang
Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310003, Zhejiang Province, China
4 shared publicationsRong Huang
Department of Gastroenterology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing 314000, Zhejiang Province, China
4 shared publicationsMeng-Lin Li
Department of Gastroenterology, Jinhua Fifth Hospital, Jinhua 321000, Zhejiang Province, China
3 shared publicationsWan-Ting Cao
Department of Gastroenterology, Beilun District Hospital of Traditional Chinese Medicine, Ningbo 315800, Zhejiang Province, China
3 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-19
Efficacy and Safety of Upadacitinib for Refractory Inflammatory Bowel Disease: A Multicenter Real-World Observational Study
Background: Although Upadacitinib has proven success in inflammatory bowel diseases (IBD), there is less data on its efficacy and safety in Asian patients with refractory IBD. Methods: This multicenter study evaluated the real-world effectiveness and safety of UPA in patients with refractory IBD. This multicenter retrospective cohort analysis included adult refractory IBD patients who received UPA therapy at three tertiary hospitals from January 2023 to March 2025. Clinical, endoscopic, and laboratory outcomes were effectiveness goals. Safety measures included AEs and and rates of discontinuation. Results: A total of 80 eligible patients were enrolled, including 52 with CD and 28 with UC. During the induction period, for CD: steroid-free clinical remission: 59.6%; clinical response: 61.5%; endoscopic remission: 30.8%; endoscopic response: 57.7%. For UC, steroid-free clinical remission: 67.9%; clinical response: 71.4%; endoscopic remission: 46.4%; endoscopic response: 60.7%. In the maintenance phase (12 months), CD had 78.8% steroid-free clinical remission and 75.0% endoscopic remission. UC had 85.7% steroid-free clinical remission and 78.6% endoscopic remission. Inflammatory indicators and nutritional parameters improved significantly. The incidence of adverse events in CD and UC was 23.1% and 14.3%, respectively, and the discontinuation rates during the 12-month maintenance treatment period were 7.1% and 21.5%, respectively. The most common adverse reaction is acne (8.75%). Conclusion: UPA demonstrated robust real-world effectiveness and an acceptable safety profile in Asian patients with refractory IBD.
- 1 March 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-19
Open AccessEfficacy and Safety of Upadacitinib for Refractory Inflammatory Bowel Disease: A Multicenter Real-World Observational Study
Background: Although Upadacitinib has proven success in inflammatory bowel diseases (IBD), there is less data on its efficacy and safety in Asian patients with refractory IBD. Methods: This multicenter study evaluated the real-world effectiveness and safety of UPA in patients with refractory IBD. This multicenter retrospective cohort analysis included adult refractory IBD patients who received UPA therapy at three tertiary hospitals from January 2023 to March 2025. Clinical, endoscopic, and laboratory outcomes were effectiveness goals. Safety measures included AEs and and rates of discontinuation. Results: A total of 80 eligible patients were enrolled, including 52 with CD and 28 with UC. During the induction period, for CD: steroid-free clinical remission: 59.6%; clinical response: 61.5%; endoscopic remission: 30.8%; endoscopic response: 57.7%. For UC, steroid-free clinical remission: 67.9%; clinical response: 71.4%; endoscopic remission: 46.4%; endoscopic response: 60.7%. In the maintenance phase (12 months), CD had 78.8% steroid-free clinical remission and 75.0% endoscopic remission. UC had 85.7% steroid-free clinical remission and 78.6% endoscopic remission. Inflammatory indicators and nutritional parameters improved significantly. The incidence of adverse events in CD and UC was 23.1% and 14.3%, respectively, and the discontinuation rates during the 12-month maintenance treatment period were 7.1% and 21.5%, respectively. The most common adverse reaction is acne (8.75%). Conclusion: UPA demonstrated robust real-world effectiveness and an acceptable safety profile in Asian patients with refractory IBD.
- Open Access
- 1 December 2025
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 15 (12) , 12812-12822
Optimizing computed tomography enterography with virtual monoenergetic imaging of second-generation dual-layer spectral CT in inflammatory bowel disease
Second-generation dual-layer spectral computed tomography enterography (DLCTE) provides advanced virtual monoenergetic imaging (VMI) that may overcome conventional computed tomography (CT) enterography limitations in inflammatory bowel disease (IBD). This study aimed to identify the optimal VMI energy level in spectral CT enterography for IBD using quantitative and qualitative image quality assessments. This case-control study retrospectively analyzed 44 patients with endoscopically confirmed active IBD undergoing DLCTE. Conventional polyenergetic images (PEIs) and VMIs (40–100 keV, 10-keV increments) were reconstructed across non-contrast, arterial, and venous phases. Quantitative metrics [contrast-to-noise ratio (CNR), signal-to-noise ratio (SNR), CT attenuation, image noise] and subjective image quality (5-point Likert scale) were compared between PEIs and VMIs. Quantitative analysis revealed that VMI 40 keV achieved peak performance: highest CT attenuation values (AV) [non-contrast: 57.7±13.2 Hounsfield units (HU) vs. PEI 40.4±7.2 HU, P0.05), VMI ≥60 keV demonstrated significantly reduced noise (P<0.001). In subjective analyses, 40 keV VMI was consistently identified as the optimal reconstruction parameter among low-energy VMIs, receiving the highest ratings for overall image quality. The dual-layer detector spectral CT low-level VMI can optimize the image quality of CTE in IBD, and is useful to evaluate the intestinal inflammatory range. Among them, the VMI 60 keV imaging has the best display and can increase the diagnostic confidence in active IBD, and it is suitable for clinical promotion and use.
- 1 December 2025
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 15 (12) , 12812-12822
Open AccessOptimizing computed tomography enterography with virtual monoenergetic imaging of second-generation dual-layer spectral CT in inflammatory bowel disease
Second-generation dual-layer spectral computed tomography enterography (DLCTE) provides advanced virtual monoenergetic imaging (VMI) that may overcome conventional computed tomography (CT) enterography limitations in inflammatory bowel disease (IBD). This study aimed to identify the optimal VMI energy level in spectral CT enterography for IBD using quantitative and qualitative image quality assessments. This case-control study retrospectively analyzed 44 patients with endoscopically confirmed active IBD undergoing DLCTE. Conventional polyenergetic images (PEIs) and VMIs (40–100 keV, 10-keV increments) were reconstructed across non-contrast, arterial, and venous phases. Quantitative metrics [contrast-to-noise ratio (CNR), signal-to-noise ratio (SNR), CT attenuation, image noise] and subjective image quality (5-point Likert scale) were compared between PEIs and VMIs. Quantitative analysis revealed that VMI 40 keV achieved peak performance: highest CT attenuation values (AV) [non-contrast: 57.7±13.2 Hounsfield units (HU) vs. PEI 40.4±7.2 HU, P0.05), VMI ≥60 keV demonstrated significantly reduced noise (P<0.001). In subjective analyses, 40 keV VMI was consistently identified as the optimal reconstruction parameter among low-energy VMIs, receiving the highest ratings for overall image quality. The dual-layer detector spectral CT low-level VMI can optimize the image quality of CTE in IBD, and is useful to evaluate the intestinal inflammatory range. Among them, the VMI 60 keV imaging has the best display and can increase the diagnostic confidence in active IBD, and it is suitable for clinical promotion and use.
- Open Access
- 28 April 2025
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 33 (4) , 261-267
Progress in understanding of relationship between blood concentrations of ustekinumab and clinical outcomes of inflammatory bowel disease
乌司奴单抗由于其疗效及安全性被广泛用于免疫性疾病的治疗, 而近年来有研究发现部分患者在长期用药过程中通过调整用药策略, 提高药物浓度可明显改善患者预后. 治疗药物监测能够反应患者体内乌司奴单抗血药浓度, 提供基于药物浓度的治疗策略决定. 本综述阐述了乌司奴单抗不同药物浓度与疗效及临床结局关系, 并基于现有文献探讨基于治疗药物监测的个体化治疗策略对于临床治疗的价值.
- 28 April 2025
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 33 (4) , 261-267
Open AccessProgress in understanding of relationship between blood concentrations of ustekinumab and clinical outcomes of inflammatory bowel disease
乌司奴单抗由于其疗效及安全性被广泛用于免疫性疾病的治疗, 而近年来有研究发现部分患者在长期用药过程中通过调整用药策略, 提高药物浓度可明显改善患者预后. 治疗药物监测能够反应患者体内乌司奴单抗血药浓度, 提供基于药物浓度的治疗策略决定. 本综述阐述了乌司奴单抗不同药物浓度与疗效及临床结局关系, 并基于现有文献探讨基于治疗药物监测的个体化治疗策略对于临床治疗的价值.
- Open Access
- 28 February 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 31 (8) , 100227
Mechanism of Wuling powder modulating proBDNF/p75NTR/sortilin and BDNF/TrkB pathways in the treatment of ulcerative colitis complicated with depression
BACKGROUND Ulcerative colitis (UC) is a chronic inflammatory disease affecting the colon. The most common psychological issue in UC patients is varying degrees of depression, which affects the condition and quality of life of UC patients and may lead to deterioration of the patient’s condition. UC drugs combined with antianxiety and antidepression drugs can alleviate symptoms of both depression and UC. Brain-derived neurotrophic factor (BDNF) precursor (proBDNF)/p75 neurotrophin receptor (p75NTR)/sortilin and BDNF/tropomyosin receptor kinase B (TrkB) signalling balance is essential for maintaining brain homeostasis and preventing the development of depressive behaviours. AIM To explore the mechanism by which Wuling powder regulates the proBDNF/ p75NTR/sortilin and BDNF/TrkB pathways in the treatment of UC with depression. METHODS Depression was established in C57BL/6J mice via chronic restraint stress, and the UC model was induced with dextran sodium sulfate (DSS). In the treatment stage, mesalazine (MS) was the basic treatment, Wuling powder was the experimental treatment, and fluoxetine was the positive control drug for treating depression. Changes in intestinal mucosal inflammation, behaviour, and the proBDNFp75NTR/sortilin and BDNF/TrkB pathways were evaluated. RESULTS In the depression groups, Wuling powder decreased the immobility time, increased the distance travelled in the central zone and the total distance travelled, and restored balance in the proBDNF/p75NTR/sortilin and BDNF/TrkB signalling pathways. In the DSS and chronic restraint stress + DSS groups, immobility time increased, distance travelled in the central zone and total distance travelled decreased, activity of the proBDNF/p75NTR/ sortilin pathway was upregulated, and activity of the BDNF/TrkB pathway was downregulated, indicating that mice with UC often have comorbid depression. Compared with those of MS alone, Wuling powder combined with MS further decreased the colon histopathological scores and the expression levels of tumor necrosis factor-alpha and interleukin-6 mRNAs. CONCLUSION This study confirmed that Wuling powder may play an antidepressant role by regulating the balance of the proBDNF/p75NTR/sortilin and BDNF/TrkB signalling pathways and further relieve intestinal inflammation in UC.
- 28 February 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 31 (8) , 100227
Open AccessMechanism of Wuling powder modulating proBDNF/p75NTR/sortilin and BDNF/TrkB pathways in the treatment of ulcerative colitis complicated with depression
BACKGROUND Ulcerative colitis (UC) is a chronic inflammatory disease affecting the colon. The most common psychological issue in UC patients is varying degrees of depression, which affects the condition and quality of life of UC patients and may lead to deterioration of the patient’s condition. UC drugs combined with antianxiety and antidepression drugs can alleviate symptoms of both depression and UC. Brain-derived neurotrophic factor (BDNF) precursor (proBDNF)/p75 neurotrophin receptor (p75NTR)/sortilin and BDNF/tropomyosin receptor kinase B (TrkB) signalling balance is essential for maintaining brain homeostasis and preventing the development of depressive behaviours. AIM To explore the mechanism by which Wuling powder regulates the proBDNF/ p75NTR/sortilin and BDNF/TrkB pathways in the treatment of UC with depression. METHODS Depression was established in C57BL/6J mice via chronic restraint stress, and the UC model was induced with dextran sodium sulfate (DSS). In the treatment stage, mesalazine (MS) was the basic treatment, Wuling powder was the experimental treatment, and fluoxetine was the positive control drug for treating depression. Changes in intestinal mucosal inflammation, behaviour, and the proBDNFp75NTR/sortilin and BDNF/TrkB pathways were evaluated. RESULTS In the depression groups, Wuling powder decreased the immobility time, increased the distance travelled in the central zone and the total distance travelled, and restored balance in the proBDNF/p75NTR/sortilin and BDNF/TrkB signalling pathways. In the DSS and chronic restraint stress + DSS groups, immobility time increased, distance travelled in the central zone and total distance travelled decreased, activity of the proBDNF/p75NTR/ sortilin pathway was upregulated, and activity of the BDNF/TrkB pathway was downregulated, indicating that mice with UC often have comorbid depression. Compared with those of MS alone, Wuling powder combined with MS further decreased the colon histopathological scores and the expression levels of tumor necrosis factor-alpha and interleukin-6 mRNAs. CONCLUSION This study confirmed that Wuling powder may play an antidepressant role by regulating the balance of the proBDNF/p75NTR/sortilin and BDNF/TrkB signalling pathways and further relieve intestinal inflammation in UC.
- Open Access
- 28 October 2024
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 32 (10) , 742-749
Progress in research of corticotropin-releasing hormone receptor 2 in inflammatory bowel disease
肾上腺皮质激素释放激素家族成员及其受体广泛分布于中枢及外周组织, 参与机体心血管、代谢、免疫反应和炎症等方面的调节. 促肾上腺皮质激素释放激素受体2(corticotropin-releasing hormone receptor 2, CRHR2)为其特异性受体之一, 它可以缓冲应激导致的肠道高敏感性、影响肠道微生物组成和多样性、具有很强的抗炎能力, 同时还可以调节肠上皮细胞的增殖和凋亡过程, 促进肠粘膜修复. 近年来研究表明, 在炎症性肠病(inflammatory bowel disease, IBD)患者的结肠组织中检测到CRHR2的含量与正常人体肠道组织存在明显差异, 有人认为 CRHR2可能是潜在的IBD治疗靶点. 本文对CRHR2的生理功能及其与IBD之间的临床相关性进行综述, 旨在探索CRHR2在IBD治疗中的具体作用机制和潜在的临床应用价值, 为将来开发更多有效的IBD的治疗手段提供依据.
- 28 October 2024
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 32 (10) , 742-749
Open AccessProgress in research of corticotropin-releasing hormone receptor 2 in inflammatory bowel disease
肾上腺皮质激素释放激素家族成员及其受体广泛分布于中枢及外周组织, 参与机体心血管、代谢、免疫反应和炎症等方面的调节. 促肾上腺皮质激素释放激素受体2(corticotropin-releasing hormone receptor 2, CRHR2)为其特异性受体之一, 它可以缓冲应激导致的肠道高敏感性、影响肠道微生物组成和多样性、具有很强的抗炎能力, 同时还可以调节肠上皮细胞的增殖和凋亡过程, 促进肠粘膜修复. 近年来研究表明, 在炎症性肠病(inflammatory bowel disease, IBD)患者的结肠组织中检测到CRHR2的含量与正常人体肠道组织存在明显差异, 有人认为 CRHR2可能是潜在的IBD治疗靶点. 本文对CRHR2的生理功能及其与IBD之间的临床相关性进行综述, 旨在探索CRHR2在IBD治疗中的具体作用机制和潜在的临床应用价值, 为将来开发更多有效的IBD的治疗手段提供依据.
- 31 July 2024
- Published by Elsevier in Gastroenterology
- Vol. 168 (3) , 461-465
A Rare Cause of Blood in Stool and Anemia
- 31 July 2024
- Published by Elsevier in Gastroenterology
- Vol. 168 (3) , 461-465
A Rare Cause of Blood in Stool and Anemia
- Open Access
- 28 March 2024
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 32 (3) , 221-227
Progress in understanding of relationship between use of biological agents and risk of malignant tumors in patients with inflammatory bowel disease
炎症性肠病(inflammation bowel disease, IBD)作为一种慢性疾病需终身治疗, 使用生物制剂开展靶向治疗是当前IBD的主要治疗方法. 随着IBD合并恶性肿瘤患者的逐渐增多, 生物制剂与IBD患者恶性肿瘤的发生风险之间的关系日益引起关注. 本文对生物制剂的使用与否与IBD患者恶性肿瘤的发生和发展风险进行综述, 以期为IBD患者的临床用药决策提供参考.
- 28 March 2024
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 32 (3) , 221-227
Open AccessProgress in understanding of relationship between use of biological agents and risk of malignant tumors in patients with inflammatory bowel disease
炎症性肠病(inflammation bowel disease, IBD)作为一种慢性疾病需终身治疗, 使用生物制剂开展靶向治疗是当前IBD的主要治疗方法. 随着IBD合并恶性肿瘤患者的逐渐增多, 生物制剂与IBD患者恶性肿瘤的发生风险之间的关系日益引起关注. 本文对生物制剂的使用与否与IBD患者恶性肿瘤的发生和发展风险进行综述, 以期为IBD患者的临床用药决策提供参考.
- Open Access
- 8 November 2023
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 31 (21) , 896-903
Role of tryptophan metabolism in inflammatory bowel disease
炎症性肠病(inflammatory bowel disease, IBD)包括溃疡性结肠炎和克罗恩病, 其发病机制与肠道菌群紊乱密切相关. 肠道菌群紊乱导致的肠道微环境异常影响氨基酸的代谢. 色氨酸作为人体必需氨基酸, 其代谢产物参与调节免疫、神经元功能和肠道稳态等. IBD疾病的发生与发展伴随色氨酸的缺乏或代谢异常. 本综述主要介绍了肠道菌群代谢物色氨酸及其代谢产物与IBD疾病发生与发展之间的关系, 并为未来预测IBD疾病活动的诊断方法和治疗IBD的方案提供了新思路.
- 8 November 2023
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 31 (21) , 896-903
Open AccessRole of tryptophan metabolism in inflammatory bowel disease
炎症性肠病(inflammatory bowel disease, IBD)包括溃疡性结肠炎和克罗恩病, 其发病机制与肠道菌群紊乱密切相关. 肠道菌群紊乱导致的肠道微环境异常影响氨基酸的代谢. 色氨酸作为人体必需氨基酸, 其代谢产物参与调节免疫、神经元功能和肠道稳态等. IBD疾病的发生与发展伴随色氨酸的缺乏或代谢异常. 本综述主要介绍了肠道菌群代谢物色氨酸及其代谢产物与IBD疾病发生与发展之间的关系, 并为未来预测IBD疾病活动的诊断方法和治疗IBD的方案提供了新思路.
- Open Access
- 8 May 2023
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 31 (9) , 347-351
Relationship between gastroesophageal reflux disease and periodontitis
胃食管反流病是指胃十二指肠内容物反流入食管、口腔、咽喉或肺引起的相关表现. 近期研究报道胃食管反流病与牙周炎之间可能存在着一定的相关性. 牙周炎是常见的口腔疾病之一. 本文就胃食管反流病的口腔表现、胃食管反流病与牙周炎关系的研究进展作一综述.
- 8 May 2023
- Published by Baishideng Publishing Group Inc. in World Chinese Journal of Digestology
- Vol. 31 (9) , 347-351
Open AccessRelationship between gastroesophageal reflux disease and periodontitis
胃食管反流病是指胃十二指肠内容物反流入食管、口腔、咽喉或肺引起的相关表现. 近期研究报道胃食管反流病与牙周炎之间可能存在着一定的相关性. 牙周炎是常见的口腔疾病之一. 本文就胃食管反流病的口腔表现、胃食管反流病与牙周炎关系的研究进展作一综述.